SCHEMBL30411571

CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)CC

nearest known ligand 0.77

Predicted protein targets (top 8)

	gene	UniProt	supporting neighbours	confidence
▸	PTH1R	Q03431	10/20	0.77

▸	GLP1R	P43220	5/20	0.74

▸	CCKBR	P32239	1/20	0.73

▸	ECE1	P42892	1/20	0.70

▸	MUS81	Q96NY9	1/20	0.70

▸	NR3C1	P04150	3/20	0.69

▸	RXFP1	Q9HBX9	1/20	0.68

▸	GRPR	P30550	1/20	0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL31396476	0.97	PTH1R (0.74)	PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL29412274	0.94	GLP1R (0.73)	PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL30148541	0.94	NR3C1 (0.74)	PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL30744286	0.94	NR3C1 (0.71)	PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL29395456	0.91	GLP1R (0.78)	PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL30683162	0.91	GLP1R (0.81)	PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL29357856	0.91	GLP1R (0.77)	PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL29360422	0.91	GLP1R (0.88)	PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL30744278	0.91	GRPR (0.69)	PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL29540128	0.91	GLP1R (0.79)	PTH1RGLP1RCCKBRECE1MUS81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12312392-B2	Methods and composition involving thermophilic fibronectin type III (FN3) monobodies	THE UNIVERSITY OF CHICAGO (US)	2025-05-27	—	—	US	disclosed
US-20240018216-A1	METHODS AND COMPOSITION INVOLVING THERMOPHILIC FIBRONECTIN TYPE III (FN3) MONOBODIES	THE UNIVERSITY OF CHICAGO (US)	2024-01-18	—	—	US	disclosed
US-11680091-B2	Methods and composition involving thermophilic fibronectin type III (FN3) monobodies	THE UNIVERSITY OF CHICAGO (US)	2023-06-20	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11680091-B2	Methods and composition involving thermophilic fibronectin type III (FN3) monobodies	FN1, F13B, FNTB	PTH1R 2170/4885GLP1R 4070/4885CCKBR 2197/4885
US-20240018216-A1	METHODS AND COMPOSITION INVOLVING THERMOPHILIC FIBRONECTIN TYPE III (FN3) MONOBODIES	FN1, F13B, FNTB	PTH1R 2170/4885GLP1R 4070/4885CCKBR 2197/4885
US-12312392-B2	Methods and composition involving thermophilic fibronectin type III (FN3) monobodies	FN1, F13B, FNTB	PTH1R 2170/4885GLP1R 4070/4885CCKBR 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.